246 related articles for article (PubMed ID: 29671345)
21. Introducing a new estimator and test for the weighted all-cause hazard ratio.
Ozga AK; Rauch G
BMC Med Res Methodol; 2019 Jun; 19(1):118. PubMed ID: 31185922
[TBL] [Abstract][Full Text] [Related]
22. Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysis.
Mukhopadhyay P; Ye J; Anderson KM; Roychoudhury S; Rubin EH; Halabi S; Chappell RJ
JAMA Oncol; 2022 Sep; 8(9):1294-1300. PubMed ID: 35862037
[TBL] [Abstract][Full Text] [Related]
23. On confidence intervals for the hazard ratio in randomized clinical trials.
Lin DY; Dai L; Cheng G; Sailer MO
Biometrics; 2016 Dec; 72(4):1098-1102. PubMed ID: 27123760
[TBL] [Abstract][Full Text] [Related]
24. Stochastic curtailment tests for phase II trial with time-to-event outcome using the concept of relative time in the case of non-proportional hazards.
Sharma P; Phadnis MA
J Biopharm Stat; 2024 Jul; 34(4):596-611. PubMed ID: 37574976
[TBL] [Abstract][Full Text] [Related]
25. A novel sample size formula for the weighted log-rank test under the proportional hazards cure model.
Xiong X; Wu J
Pharm Stat; 2017 Jan; 16(1):87-94. PubMed ID: 27860138
[TBL] [Abstract][Full Text] [Related]
26. Comparison of survival distributions in clinical trials: A practical guidance.
Chen X; Wang X; Chen K; Zheng Y; Chappell RJ; Dey J
Clin Trials; 2020 Oct; 17(5):507-521. PubMed ID: 32594788
[TBL] [Abstract][Full Text] [Related]
27. A sequential testing approach to detecting multiple change points in the proportional hazards model.
He P; Fang L; Su Z
Stat Med; 2013 Mar; 32(7):1239-45. PubMed ID: 22933339
[TBL] [Abstract][Full Text] [Related]
28. Weighted log-rank test for time-to-event data in immunotherapy trials with random delayed treatment effect and cure rate.
Liu S; Chu C; Rong A
Pharm Stat; 2018 Sep; 17(5):541-554. PubMed ID: 30058101
[TBL] [Abstract][Full Text] [Related]
29. Group sequential designs for cancer immunotherapy trial with delayed treatment effect.
Wu J; Li Y; Zhu L
J Biopharm Stat; 2024 Jan; 34(1):1-15. PubMed ID: 36740768
[TBL] [Abstract][Full Text] [Related]
30. Deviation from the Proportional Hazards Assumption in Randomized Phase 3 Clinical Trials in Oncology: Prevalence, Associated Factors, and Implications.
Rahman R; Fell G; Ventz S; Arfé A; Vanderbeek AM; Trippa L; Alexander BM
Clin Cancer Res; 2019 Nov; 25(21):6339-6345. PubMed ID: 31345838
[TBL] [Abstract][Full Text] [Related]
31. A comparison of methods for fixed effects meta-analysis of individual patient data with time to event outcomes.
Tudur Smith C; Williamson PR
Clin Trials; 2007; 4(6):621-30. PubMed ID: 18042571
[TBL] [Abstract][Full Text] [Related]
32. Meta-analysis of time-to-event outcomes from randomized trials using restricted mean survival time: application to individual participant data.
Wei Y; Royston P; Tierney JF; Parmar MK
Stat Med; 2015 Sep; 34(21):2881-98. PubMed ID: 26099573
[TBL] [Abstract][Full Text] [Related]
33. A win ratio approach for comparing crossing survival curves in clinical trials.
Zheng S; Wang D; Qiu J; Chen T; Gamalo M
J Biopharm Stat; 2023 Jul; 33(4):488-501. PubMed ID: 36749067
[TBL] [Abstract][Full Text] [Related]
34. Quantifying the average of the time-varying hazard ratio via a class of transformations.
Chen Q; Zeng D; Ibrahim JG; Chen MH; Pan Z; Xue X
Lifetime Data Anal; 2015 Apr; 21(2):259-79. PubMed ID: 25073864
[TBL] [Abstract][Full Text] [Related]
35. Hazard ratio estimation and inference in clinical trials with many tied event times.
Mehrotra DV; Zhang Y
Stat Med; 2018 Nov; 37(25):3547-3556. PubMed ID: 29900572
[TBL] [Abstract][Full Text] [Related]
36. A simulation study comparing the power of nine tests of the treatment effect in randomized controlled trials with a time-to-event outcome.
Royston P; B Parmar MK
Trials; 2020 Apr; 21(1):315. PubMed ID: 32252820
[TBL] [Abstract][Full Text] [Related]
37. A non-parametric procedure for evaluating treatment effect in the meta-analysis of survival data.
Moodie PF; Nelson NA; Koch GG
Stat Med; 2004 Apr; 23(7):1075-93. PubMed ID: 15057879
[TBL] [Abstract][Full Text] [Related]
38. Robust group sequential designs for trials with survival endpoints and delayed response.
Ghosh P; Ristl R; König F; Posch M; Jennison C; Götte H; Schüler A; Mehta C
Biom J; 2022 Feb; 64(2):343-360. PubMed ID: 34935177
[TBL] [Abstract][Full Text] [Related]
39. Restricted mean survival time to estimate an intervention effect in a cluster randomized trial.
Vilain-Abraham FL; Tavernier E; Dantan E; Desmée S; Caille A
Stat Methods Med Res; 2023 Oct; 32(10):2016-2032. PubMed ID: 37559486
[TBL] [Abstract][Full Text] [Related]
40. The Net Chance of a Longer Survival as a Patient-Oriented Measure of Treatment Benefit in Randomized Clinical Trials.
Péron J; Roy P; Ozenne B; Roche L; Buyse M
JAMA Oncol; 2016 Jul; 2(7):901-5. PubMed ID: 27124210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
